Biogen: Reports of Its Demise ‘Have (Probably!) Been Greatly Exaggerated’

When it comes to Biogen (BIIB), Bernstein’s Geoffrey Porges and team insist “reports of the core’s demise have (probably!) been greatly exaggerated.” Doesn’t that probably make you feel good? Anyway, here’s why: Associated Press After accounting for net cash ($4bn or $17/share), and the value of the pipeline from our prior analysis, and the value [...]